# Naltrexone + Bupropion

## Contrave 8/90mg extended-release

| TAH Drug Code      | [OCONT](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OCONT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | An adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Dosing             | Extended-Release Tablets: Naltrexone 8mg + Bupropion 90mg. CONTRAVE dosing should be escalated according to the following schedule: Week 1: 1 tablet in the morning. Week 2: 1 tablet BID. Week 3: 2 tablets in the morning and 1 tablet in the evening. Week 4 - Onward: 2 tablets BID. A total daily dosage of two CONTRAVE 8 mg/90 mg tablets twice daily (32 mg/360 mg) is reached at the start of Week 4.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Contraindications  | Uncontrolled hypertension. Seizure disorder or a history of seizures. Use of other bupropion-containing products (including, but not limited to, WELLBUTRIN, WELLBUTRIN SR, WELLBUTRIN XL, and APLENZIN). Bulimia or anorexia nervosa, which increase the risk for seizure. Chronic opioid or opiate agonist (e.g., methadone) or partial agonists (e.g., buprenorphine) use, or acute opiate withdrawal. Patients undergoing an abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs. Concomitant administration of monoamine oxidase inhibitors (MAOI). At least 14 days should elapse between discontinuation of MAOI and initiation of treatment with CONTRAVE. There is an increased risk of hypertensive reactions when CONTRAVE is used concomitantly with MAOIs. Starting CONTRAVE in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is also contraindicated. Known allergy to bupropion, naltrexone or any other component of CONTRAVE. Anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported with bupropion. Pregnancy. |
| Adverse Effects    | Common Gastrointestinal: Constipation (19.2% ), Diarrhea (7.1% ), Nausea (32.5% ), Vomiting (10.7% ), Xerostomia (8.1% ) Neurologic: Dizziness (9.9% ), Headache (17.6% ), Insomnia (9.2% ) Psychiatric: Anxiety (4.2% ) Serious Cardiovascular: Hypertension (3.2% ), Increased heart rate, Myocardial infarction (Less than 2% ) Dermatologic: Erythema multiforme (Rare ), Stevens-Johnson syndrome (Rare ) Endocrine metabolic: Hypoglycemia Gastrointestinal: Cholecystitis (Less than 2% ), Hematochezia (Less than 2% ) Hepatic: Hepatotoxicity Immunologic: Anaphylaxis, Delayed hypersensitivity disorder Musculoskeletal: Intervertebral disc prolapse (Less than 2% ) Neurologic: Amnesia (Less than 2% ), Seizure (0.1% ) Ophthalmic: Angle-closure glaucoma Psychiatric: Depression (6.3% to 7.1% ), Mania, Psychiatric symptom, Suicidal thoughts (0.03% ) Renal: Infectious disorder of kidney (Less than 2% ), Serum creatinine raised (Less than 2% ) Respiratory: Pneumonia (Less than 2% )                                                                                                                                  |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Moderate Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| More Info          | [UpToDate](https://www.uptodate.com/contents/naltrexone-and-bupropion-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

